Home›Research›Compare›Retatrutide vs Semaglutide
Peptide ComparisonRetatrutide vs Semaglutide
Both are Metabolic peptides.
Retatrutide
GLP-3
Half-life: ~6 days
96 providers listed
Semaglutide
GLP-1
Half-life: ~7 days (once-weekly dosing)
806 providers listed
Semaglutide is FDA-approved, while Retatrutide is investigational — the clearest structural difference between them.
Retatrutide
Half-life
~6 days
Semaglutide
Half-life
~7 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Retatrutide |
| Further along in FDA review | Semaglutide |
| Less frequent dosing (longer half-life) | Semaglutide |
| Oral administration option | Semaglutide |
| More provider options (96 vs 806) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Retatrutide
Semaglutide
Retatrutide
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Revi…
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
Design of the TRIUMPH phase 3 clinical trial programme for retatrutide in obesity and cardiometabolic disease
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
+6 more
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
+1 more
About Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Retatrutide
Class-based (investigational)
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Retatrutide
Semaglutide
Where to source these peptides
Retatrutide
96 listed
Browse directory →
Providers offeringSemaglutide
806 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Retatrutide vs Semaglutide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/retatrutide/semaglutide